American Diabetes Association Virtual 80th Scientific Sessions (ADA 2020)

US 12 June 2020 - 16 June 2020

VERTIS CV highlights CV safety of ertugliflozin in T2D

07 Aug 2020 by

Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.

VERTIS CV highlights CV safety of ertugliflozin in T2D

07 Aug 2020

EMPRISE reinforces CV benefits of empagliflozin

28 Jul 2020 by

The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE⁺ study presented at ADA 2020.

EMPRISE reinforces CV benefits of empagliflozin

28 Jul 2020

Does spacing pregnancies help women with gestational diabetes?

28 Jul 2020 by

Women with a history of gestational diabetes were 50 percent more likely to have a short interval between pregnancies compared to women without the condition, suggests a new study.

Does spacing pregnancies help women with gestational diabetes?

28 Jul 2020

Dapagliflozin may prevent new-onset T2D

23 Jul 2020 by

Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.

Dapagliflozin may prevent new-onset T2D

23 Jul 2020

Insulin detemir use not tied to adverse pregnancy outcomes

18 Jul 2020 by

The use of insulin detemir among women with pre-existing diabetes was not associated with an increased risk of negative pregnancy outcomes, such as major congenital malformations and perinatal or neonatal deaths, compared with other basal insulins, according to the EVOLVE* study.

Insulin detemir use not tied to adverse pregnancy outcomes

18 Jul 2020

Icosapent ethyl may REDUCE CV risk in diabetes

17 Jul 2020 by

Icosapent ethyl may reduce the risk of cardiovascular (CV) events in patients with diabetes mellitus (DM) taking statins, according to findings of REDUCE-IT DIABETES presented at ADA 2020.

Icosapent ethyl may REDUCE CV risk in diabetes

17 Jul 2020

Next-gen auto insulin pump trumps current tech for glycaemic control in T1D

15 Jul 2020 by

The next-generation automated insulin delivery (AID) system significantly improved daytime glycaemic control without increasing hypoglycaemia over the current 670G hybrid closed-loop system on the market in young patients with type 1 diabetes (T1D), according to the FLAIR* trial presented during the ADA 2020 Annual Meeting.

Next-gen auto insulin pump trumps current tech for glycaemic control in T1D

15 Jul 2020

Plant-based diet before pregnancy may cut GDM risk

13 Jul 2020 by

Women who follow a healthy plant-based diet before pregnancy have a lower risk of developing gestational diabetes mellitus (GDM), suggests a large, prospective cohort study presented at the ADA 2020 Annual Meeting.

Plant-based diet before pregnancy may cut GDM risk

13 Jul 2020

Dorzagliatin SEEDs good outcomes in T2D

07 Jul 2020 by

The novel dual-acting glucokinase activator (GKA) dorzagliatin provides good glycaemic control and has a favourable safety profile in Chinese patients with type 2 diabetes (T2D), the phase III SEED* study has shown.

Dorzagliatin SEEDs good outcomes in T2D

07 Jul 2020

Ipragliflozin shows benefits for T2D patients with NAFLD

06 Jul 2020 by

Long-term use of ipragliflozin improves obesity, glycaemic control, and hepatic outcomes in patients with type 2 diabetes (T2D) who developed nonalcoholic fatty liver disease (NAFLD), a study shows.

Ipragliflozin shows benefits for T2D patients with NAFLD

06 Jul 2020